1290629-77-4

Basic information

• Product Name: (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-6-trityloxymethyl-tetrahydro-pyran-3,4,5-triol
• Synonyms: (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-6-trityloxymethyl-tetrahydro-pyran-3,4,5-triol
• CAS NO: 1290629-77-4
• Molecular Weight: 651.199
• Mol File: 1290629-77-4.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-6-trityloxymethyl-tetrahydro-pyran-3,4,5-triol(CAS DataBase Reference)
• NIST Chemistry Reference: (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-6-trityloxymethyl-tetrahydro-pyran-3,4,5-triol(1290629-77-4)
• EPA Substance Registry System: (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-6-trityloxymethyl-tetrahydro-pyran-3,4,5-triol(1290629-77-4)

Safety Data

• Hazardous Substances Data: 1290629-77-4(Hazardous Substances Data)

Upstream product

• 461432-26-8 dapagliflozin 
• 76-83-5 trityl chloride 

Downstream Products

• 1290629-80-9 (2S,3S,4R,5S,6S)-3,4,5-tris-benzyloxy-6-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]tetrahydropyran-2-carbaldehyde 
• 1290629-85-4 (3S,4R,5R,6S)-6-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-2,2-dimethyl-tetrahydro-pyran-3,4,5-triol 
• 1290629-84-3 (3S,4R,5S,6S)-3,4,5-tris-benzyloxy-6-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-2,2-dimethyl-tetrahydro-pyran 
• 1290629-83-2 (3S,4R,5S,6S)-3,4,5-tris-benzyloxy-6-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-2,2-bis-iodomethyl-tetrahydro-pyran 
• 1290629-82-1 (3S,4R,5R,6S)-6-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-2,2-bis-hydroxymethyl-tetrahydro-pyran-3,4,5-triol 
• 1290629-81-0 [(3S,4R,5S,6S)-3,4,5-tris-benzyloxy-6-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-2-(hydroxymethyl)tetrahydropyran-2-yl]methanol 
• 1290629-79-6 [(2R,3R,4R,5S,6S)-3,4,5-trisbenzyloxy-6-[4-chloro-3-[(4-ethoxyphenyl)methyl]benzenyl]tetrahydropyran-2-yl]methanol 
• 1290629-76-3 (5S,6S,7R,8S)-5-(4-chloro-3-{4-[(S)-(tetrahydro-furan-3-yl)oxy]-benzyl}phenyl)-4-oxaspiro[2.5]octane-6,7,8-triol 
• 1290629-75-2 (5S,6S,7R,8S)-5-(4-chloro-3-(4-((S)-tetrahydrofuran-3-yloxy)benzyl)phenyl)-4-oxaspiro[2.5]octane-6,7,8-triyl triacetate 
• 1290629-74-1 (5S,6R,7R,8S)-5-[4-chloro-3-(4-hydroxy-benzyl)-phenyl]-4-oxa-spiro[2.5]octane-6,7,8-triol 
• 1290629-73-0 acetic acid (5S,6S,7R,8S)-7,8-diacetoxy-5-[4-chloro-3-(4-hydroxy-benzyl)-phenyl]-4-oxa-spiro[2.5]oct-6-yl ester 
• 1290629-72-9 acetic acid (5S,6S,7R,8S)-7,8-diacetoxy-5-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-4-oxa-spiro[2.5]oct-6-yl ester 
• 1290630-24-8 {4-[2-chloro-5-((5S,6S,7R,8S)-6,7,8-triacetoxy-4-oxa-spiro[2.5]oct-5-yl)-benzyl]-2-nitro-phenoxy}-acetic acid ethyl ester 
• 1290630-23-7 acetic acid (5S,6S,7R,8S)-7,8-diacetoxy-5-[4-chloro-3-(4-hydroxy-3-nitro-benzyl)-phenyl]-4-oxa-spiro[2.5]oct-6-yl ester 

Relevant articles and documents

GLYCOSIDE DERIVATIVE AND USES THEREOF

This invention relates to compounds represented by formula (I): wherein the variables are defined as herein above, which are useful for treating diseases and conditions mediated by the sodium D-glucose co-transporter (SGLT), e.g. diabetes. The invention also provides methods of treating such diseases and conditions, and compositions etc. for their treatment.

Syntheses of C-5-spirocyclic C-glycoside SGLT2 inhibitors

Several syntheses of C-5-spirocycle-containing C-glycosides are discussed. A multigram-scale synthesis capitalizing on a one-pot aldol-Cannizzaro sequence is described. Spiro oxetane formation using an unprotected penta-ol C-glycoside as substrate is also exemplified. Functional assessment of these compounds for potency and selectivity was evaluated at human SGLT2 and SGLT1.